Embedded Files
Our mission is to improve care outcomes in at risk patients
Individuals who are bedridden for one week or more are at risk for developing pressure ulcers. DuraDerma has been demonstrated to prevent the progression of pressure ulcers compared to the standard of care and other competing products.
Preclinical efficacy of DuraDerma
Locations of pressure ulcers
Locations of pressure ulcers
Pressure ulcer snapshot
Pressure ulcer snapshot
>15 million patients at risk annually in the US alone
2.5 million pressure ulcers occur in the US annually
$16 billion result in annual US healthcare spend
12.8% incidence globally in hospitalized adults
420 million global hospitalizations per year
A "never" event
A "never" event
Pressure ulcers are classified as a “never event” meaning that costs of care are not reimbursed if the patient develops an ulcer during hospitalization and hospitals are greatly incentivized to reduce the incidence and progression of pressure ulcers. Pressure ulcers also expose facilities to potential litigation and low facility quality scores, which impact reimbursement.
Pressure Ulcer Progression
Pressure ulcer progression begins with an initial epidermal ulcer and can progress to deep ulceration. Stage 1 and Stage 2 pressure ulcers from advancing into deep, high-cost wounds associated with increased morbidity, mortality, and healthcare utilization.
Pressure ulcer progression
Pressure ulcer progression
Stages of pressure ulcers
Stages of pressure ulcers
Major care markets
DuraDerma targets 5 care markets where immobility and prolonged positioning create high risk for pressure ulcer development.
Skilled nursing
Home-care
Surgical-recovery
Hospitals
Assisted living
Prevention of pressure ulcer development
Prevention of pressure ulcer development
Topical application of DuraDerma effectively prevents pressure ulcers by increasing skin collagen content, enhancing structural integrity, and preserving skin thickness.
Reduction in inflammation
Reduction in inflammation
Single and repeated topical applications of DuraDerma significantly reduce inflammatory markers, mitigating the inflammatory response that contributes to tissue degradation.
Superior to leading product
Superior to leading product
There no labeled products for the prevention of pressure ulcers or prevention of progression of early-stage (1-2) pressure ulcers. The only product that has been adopted is Cavilon® (3M), which is not specifically labeled for pressure ulcers nor for which any supporting clinical data have been reported. The standard of care is skin hygiene and rotating the patient to reduce prolonged positioning on bony prominences. Numerous medical devices are promoted as potentially able to prevent or treat pressure ulcers but none have demonstrated efficacy in large, randomized, controlled, multicenter clinical trials.
Skin regeneration and protection
Skin regeneration and protection
Topical application of DuraDerma promotes collagen deposition, ensuring long-term durability and resilience of the skin under pressure.
Page updated
Report abuse